Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians will provide coverage for its Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. Atlas Healthcare Physicians is an independent physician association serving managed care populations across Los Angeles and Orange counties. This coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.
According to Cardio Diagnostics, the Epi+Gen CHD test evaluates a patient's three-year risk of a coronary heart disease event, while the PrecisionCHD test helps diagnose coronary heart disease and identify its underlying molecular drivers. Both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, supporting broader adoption of precision cardiovascular medicine across community healthcare networks.
This partnership is significant for the healthcare industry as it brings advanced AI-driven diagnostics to managed care populations, potentially improving early detection and management of coronary heart disease. Coronary heart disease remains a leading cause of death globally, and tools that enable precise risk assessment and personalized treatment can reduce mortality and healthcare costs. For leaders in business and technology, this development highlights the growing integration of AI in healthcare, particularly in precision medicine, which is expected to drive efficiencies and better outcomes.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The latest news and updates relating to CDIO are available in the company’s newsroom at https://nnw.fm/CDIO.
For the reader, this news matters because it demonstrates how AI-powered diagnostics are moving from research into practical, reimbursed clinical use. The expansion of coverage through Atlas Healthcare Physicians could serve as a model for other insurers and healthcare networks, accelerating adoption of precision medicine. For the industry, it underscores the importance of partnerships between diagnostic companies and provider networks to scale innovative technologies. The noninvasive nature of these tests also addresses patient convenience and safety, which are critical for widespread uptake.
Overall, this announcement represents a step forward in making precision cardiovascular care more accessible, potentially impacting how heart disease is diagnosed and managed in managed care settings.
